KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) FCF Margin (2018 - 2026)

Castle Biosciences' FCF Margin history spans 8 years, with the latest figure at 22.7% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 323.0% to 22.7% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.23%, a 277.0% decrease, with the full-year FY2025 number at 8.23%, down 277.0% from a year prior.
  • FCF Margin hit 22.7% in Q4 2025 for Castle Biosciences, up from 0.74% in the prior quarter.
  • Over the last five years, FCF Margin for CSTL hit a ceiling of 107.51% in Q4 2021 and a floor of 167.47% in Q3 2021.
  • Historically, FCF Margin has averaged 10.85% across 5 years, with a median of 11.29% in 2024.
  • Biggest five-year swings in FCF Margin: tumbled -14784bps in 2021 and later surged 15218bps in 2022.
  • Tracing CSTL's FCF Margin over 5 years: stood at 107.51% in 2021, then plummeted by -125bps to 27.39% in 2022, then surged by 208bps to 29.48% in 2023, then crashed by -34bps to 19.46% in 2024, then rose by 17bps to 22.7% in 2025.
  • Business Quant data shows FCF Margin for CSTL at 22.7% in Q4 2025, 0.74% in Q3 2025, and 21.74% in Q2 2025.